3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
2
Skin Neoplasms
1
Skin Diseases
1
Neoplasms
1
Neoplasm Metastasis
1
Interventions
trametinib
4
dabrafenib
4
encorafenib
3
Oxaliplatin
3
zolbetuximab
2
selpercatinib
2
pembrolizumab
2
lenvatinib
2
larotrectinib
2
dostarlimab
2
binimetinib
2
Leucovorin
2
Fulvestrant
2
Fluorouracil
2
Cetuximab
2
Capecitabine
2
trastuzumab deruxtecan
1
tepotinib
1
telisotuzumab vedotin
1
ribociclib
1
repotrectinib
1
relatlimab
1
pralsetinib
1
pegaspargase
1
niraparib
1
blinatumomab
1
avelumab
1
asparaginase erwinia chrysanthemi recombinant
1
adagrasib
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Neoplasms
×
Vemurafenib
×
Clear all
NCT01909453
2026-02-27
COLUMBUS
Pfizer
Phase 3
Completed
921 enrolled
48 charts
1 FDA